Longitudinal stability of salivary microRNA biomarkers in children and adolescents with autism spectrum disorder.
Spit microRNAs mirror autism severity and shift within weeks of early therapy, giving BCBAs a quick, kid-friendly progress gauge.
01Research in Context
What this study did
Mason et al. (2021) tracked the same kids with autism every few months.
They collected spit tubes and ran behavior checks for about a year.
Seven tiny RNA bits in saliva were matched to social, language, and play scores.
Three of those bits were watched again after families started any early-intervention program.
What they found
The seven microRNA levels rose or fell with the children's symptom scores.
Three microRNAs shifted within three months of starting therapy.
The spit test picked up behavioral change faster than standard rating forms.
How this fits with other research
Hu et al. (2017) first said microRNAs could be autism markers but warned they were not ready for clinics. David's team now shows the markers move when behavior moves, giving the warning a path forward.
Eggleston et al. (2018) used saliva too, yet hunted mouth-bug DNA instead of RNA. Both studies reached high accuracy, proving spit is a kid-friendly goldmine for different biomarker types.
Baker et al. (2025) reviewed gut and metabolic markers and asked for long-term data. David et al. answer that call by tracking the same children over time, filling the gap the review said was missing.
Why it matters
You now have a painless, 30-second spit collection that can signal if therapy is working before your eyes see it. Add it to baseline and quarterly probes. If the microRNA pattern flattens while skills climb, you gain early proof the plan is on track. No extra blood, no fasting, no tears.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Add a saliva sample to your next baseline probe, store it frozen, and repeat in three months to watch microRNA trends alongside your skill graphs.
02At a glance
03Original abstract
BACKGROUND: Autism spectrum disorder (ASD) is a complex neurological condition with increasing prevalence. Few tools accurately predict the developmental trajectory of children with ASD. Such tools would allow clinicians to provide accurate prognoses and track the efficacy of therapeutic interventions. Salivary RNAs that reflect the genetic-environmental interactions underlying ASD may provide objective measures of symptom severity and developmental outcomes. This study investigated whether salivary RNAs previously identified in childhood ASD remain perturbed in older children. We also explored whether RNA candidates changed with therapeutic intervention. METHOD: A case-control design was used to characterize levels of 78 saliva RNA candidates among 96 children (48 ASD, 48 non-ASD, mean age: 11 years). Thirty-one children (22 ASD, 9 non-ASD developmental delay, mean age: 4 years) were followed longitudinally to explore changes of RNA candidates during early intervention. Saliva RNA and standardized behavioral assessments were collected for each participant. Associations between candidate RNAs and behavioral scores were determined in both groups via Spearman Correlation. Changes in candidate RNAs across two time-points were assessed in the younger cohort via Wilcoxon rank-sum test. RESULTS: Seven RNAs were associated with VABS-II and BASC scores in the older group ([R] >0.25, FDR< 0.15). Within the younger cohort, 12 RNAs displayed significant changes over time (FDR< 0.05). Three microRNAs were associated with behavioral scores and changed over time (miR-182-5p, miR-146b-5p, miR-374a-5p). CONCLUSION: Several salivary RNAs are strongly associated with autistic behaviors in older individuals with ASD and change as early as three months after therapy initiation in younger children. These molecules could be used to track treatment effectiveness and provide prognoses. Further validation is necessary.
Research in autism spectrum disorders, 2021 · doi:10.3389/fpsyt.2016.00176